Pubdate: Tue, 26 Jan 2016 Source: Philadelphia Inquirer, The (PA) Copyright: 2016 Philadelphia Newspapers Inc Contact: http://www.philly.com/inquirer/ Details: http://www.mapinc.org/media/340 Author: Scott E. Shapiro RESEARCH NEEDED The U.S. Drug Enforcement Administration's decision last month to relax requirements for marijuana-derived research is encouraging. The Pennsylvania Medical Society, on behalf of our members and their patients, urges that the U.S. Food and Drug Administration also work to support research that will lead to the development of safe treatment options. We also urge the FDA to reschedule marijuana from a Schedule I to a Schedule II substance to facilitate research across the country. With legislation to legalize medical marijuana pending in Pennsylvania, we are hopeful that the DEA decision will slow down state legislation on marijuana legalization in favor of FDA-approved clinical research and rescheduling of the substance. Advocates and patients want to use marijuana for illnesses and conditions despite incomplete and limited FDA research on its safety and effectiveness. Society members prefer additional research and clinical study before Pennsylvania allows medical use of marijuana. This position is aligned with the American Medical Association's policy. Dr. Scott E. Shapiro, president, Pennsylvania Medical Society, Harrisburg - --- MAP posted-by: Jay Bergstrom